Symbols

Symbols

PGEN

PGEN

Precigen shares surge 24.48% after hours following FDA approval of Papzimeos and strong Q3 results.

Biotech Stocks Rally After Strong Q3 Earnings: Vaxart and Precigen Lead the Way

Precigen shares surge 31.35% intraday as Citizens and HC Wainwright raise price targets amid PAPZIMEOS therapy launch progress and strong cash reserves.

Precigen shares surge 20.05% intraday as Q3 earnings exceed expectations and PAPZIMEOS commercialization progresses.

Precigen: HC Wainwright Raises PT to $9, Maintains Buy Rating

Precigen Inc Receives FDA Approval for Papsius, Launches in US Amid Challenges

Saturday Nov 01, 2025

Patient Capital Doubles Down on Precigen, Acquires 10.2 Million Shares

Friday Oct 17, 2025

Patient Opportunity Equity Fund Posts 14.1% Q3 Return, Initiates New Positions in UNH, CROX, MAT, IAC, and BIIB

Monday Oct 13, 2025

Precigen Reports Positive Outcomes for Rare Respiratory Disease Drug Candidate

Precigen announces long-term RRP treatment data with PAPZIMEOS.

Precigen Reports Long-Term Efficacy of Papzimeos in Recurrent Respiratory Papillomatosis

Wednesday Oct 01, 2025

Precigen Inc. Director Jeffrey B Kindler Sells Shares in Two Transactions.

Tuesday Sep 30, 2025

Precigen Announces Director Sale and Executives Buy Shares Amidst Trading.

Friday Sep 26, 2025

Precigen CFO Buys 8284 Shares at $3.62/Share and 2932 Shares at $3.42/Share.

Precigen, Inc. shares rise 1.29% premarket after FDA approval of novel immunotherapy and Cencora's support for commercial launch.

Tuesday Sep 23, 2025

Precigen Secures $125M for PAPZIMEOS Expansion and Pediatric Indications

Precigen's Papzimeos Receives Full FDA Approval, Stock Soars.

Is Precigen, Inc. on the Verge of Breakeven?

Monday Sep 22, 2025

Precigen shares rise 3.47% premarket after being added to S&P Biotechnology Select Industry Index.

Saturday Sep 20, 2025

Precigen Bolsters Financial Standing with $125 Million Credit Facility